At ONY Biotech, we are driven by innovation.

Our commitment to the development of treatments for premature babies propels us forward as a company and as an industry. Since 1985, ONY Biotech has been dedicated to the innovation of new treatments that result in better outcomes for patients and their families.

Currently, ONY Biotech has one major commercial product, Infasurf^® (calfactant), available in the market, while clinical trials for a non-invasive, aerosolized version, of the treatment were completed at the end of 2018 and are undergoing FDA review.

ONY Biotech: Treatments for premature babies.

While our motivation is simple, the science that goes into creating a lung surfactant that resembles the real thing is a little more complicated.

To create Infasurf^® (calfactant), we start by sourcing the high-quality components that are put through rigorous testing. From there, through a lavage process, we extract a surfactant that closely resembles natural surfactant.

What’s in development at ONY Biotech.

We’re always innovating at ONY Biotech. Currently, our scientists are working closely with partners at the University at Buffalo to develop acellular tissue engineered vessels as well as hydrogen detectors.

Learn more about what’s in the works.